Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003079 · ClinicalTrials.gov registry record · Phase 1
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003079 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 30 participants.
The verdict
NCT00003079, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 and high dose cytarabine in treating patients with refractory or relapsed acute myelocytic or acute lymphocytic leukemia, chronic myelogenous leukemia or refractory or relapsed lymphoblastic lymphoma.
Interventions
- DRUG cytarabine
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-09 |
| Est. Completion | 2001-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003079
The ClinicalTrials.gov registry entry for NCT00003079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00003079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003079 about?
NCT00003079 is a clinical study titled "Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 and high dose cytarabine in treating patients with refr...
What is the current status of trial NCT00003079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1997-09. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00003079?
The interventions under investigation include: cytarabine (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00003079?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.